There is a worldwide pandemic of COVID-19 caused by SARS-CoV-2.1 By January 28,2021,more than 100 million cases had been diagnosed,and more than 2 million deaths had been reported(https://coronavirus.jhu.edu/map.html).The comprehensive and in-depth elucidation of SARS-CoV-2-specific IgG responses will help us to better understand COVID-19 immunity and facilitate the precise development of neutralizing antibodies and vaccines.
Coronavirus disease 2019 is threatening thousands of millions of people around the world.In the absence of specific and highly effective medicines,the treatment of infected persons is still very challenging.As therapeutics,neutralizing antibodies(NAbs)have great potential.Many NAbs have been reported,and most target various regions on the receptor-binding domain of the spike(S)protein,or the N-terminal domain.Several NAbs and NAb cocktails have been authorized for emergency use,and more arc in clinical trials or are under development.In this review,considering the angle of binding epitopes on the S protein,we summarize the functions and the underlying mechanisms of a set of well-recognized NAbs and provide guidance for vaccine design and the combinatorial use of these antibodies.In addition,we review the NAbs and NAb cocktails that have been approved for emergency use and discuss the effectiveness of these NAbs for combating severe acute respiratory syndrome coronavirus 2 mutants.
